US2018021314A1PendingUtilityA1
Therapeutic agent for meibomian dysfunction
Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: Mar 13, 2013Filed: Oct 2, 2017Published: Jan 25, 2018
Est. expiryMar 13, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61P 9/14A61P 9/00A61P 27/04A61P 27/02A61K 31/436A61K 31/675A61K 9/0048A61K 31/453A61K 9/107A61K 9/10A61P 9/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
Claims
exact text as granted — not AI-modified1 . A method for treatment of meibomian gland dysfunction in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
2 . The method according to claim 1 , wherein the eye drop comprises 0.5% (w/v) of sirolimus.
3 . The method according to claim 1 , wherein the eye drop is administered to the eyes of the mammalian subject 1 time per day.
4 . The method according to claim 1 , wherein the eye drop is a suspension or an emulsion.
5 . The method according to claim 1 , wherein the eye drop is a suspension.
6 . The method according to claim 1 , wherein eye drop is a suspension and comprises 0.5% (w/v) of sirolimus.
7 . The method according to claim 6 , wherein the eye drop is administered to the eyes of the mammalian subject 1 time per day.Join the waitlist — get patent alerts
Track US2018021314A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.